Sermorelin
Also known as: GRF 1-29, Geref
The first 29 amino acids of GHRH for physiological GH stimulation.
Overview
Sermorelin is a truncated form of GHRH containing the first 29 amino acids, which retain full biological activity. It was the first GHRH analog approved for GH deficiency.
Mechanism of Action
Directly stimulates pituitary somatotrophs via GHRH receptors, promoting natural GH synthesis and pulsatile release. Maintains hypothalamic-pituitary feedback.
Pharmacokinetics
Very short half-life (~10-20 minutes) requiring frequent dosing. Peak GH release within 30 minutes.
Dosing Protocols
Note: These are research protocols from literature. This is not medical advice.
Standard
200-300 mcg
Once daily at bedtime
3-6 months
Before sleep for optimal GH pulse
Stacking Recommendations
Peptides that may be combined based on complementary mechanisms in research settings.
Research Areas
Key Research Findings
- 1Restored GH secretion in deficient children
- 2Improved sleep quality and deep sleep phases
- 3Maintained natural GH pulsatility
- 4Good safety profile with long-term use
Side Effects & Contraindications
Reported Side Effects
- Flushing
- Headache
- Injection site irritation
Contraindications
- Active malignancy
- Pregnancy
Safety Considerations
Well-tolerated. May lose efficacy over time due to tachyphylaxis. Less potent than modified analogs.
Storage Requirements
Store lyophilized at 2-8C
Scientific References
- 1